Home > Boards > US Listed > Medical - Drugs > Eli Lilly & Company (LLY)

This Big Pharma Stock $LLY Is Dropping And

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
ITMS Member Profile
Member Level 
Followed By 45
Posts 1,575
Boards Moderated 1
Alias Born 10/13/09
160x600 placeholder
Lilly's Taltz® (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographi... PR Newswire (US) - 6/1/2020 6:45:00 AM
Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans PR Newswire (US) - 6/1/2020 6:30:00 AM
Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treat... PR Newswire (US) - 5/31/2020 7:30:00 PM
Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Se... PR Newswire (US) - 5/31/2020 7:30:00 PM
Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung... PR Newswire (US) - 5/29/2020 9:07:00 PM
Lilly Receives U.S. FDA Approval of TAUVID™ (flortaucipir F 18 injection) for Use in Patients Being Evaluated for Alzheimer... PR Newswire (US) - 5/28/2020 7:17:00 PM
Statement from Lilly Chairman and CEO Dave Ricks on New Part D Senior Savings Model PR Newswire (US) - 5/26/2020 5:51:00 PM
Eli Lilly, Boehringer Ingelheim to Study Diabetes Drug Jardiance After Heart Attacks Dow Jones News - 5/26/2020 1:15:00 PM
Nature Publishes Preclinical Characterization and Primate Efficacy Data on Junshi Biosciences’ COVID-19 Neutralizing Antibo... GlobeNewswire Inc. - 5/26/2020 10:11:01 AM
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance'... PR Newswire (US) - 5/26/2020 8:00:00 AM
Emgality® Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in Patients with Migraine and a H... PR Newswire (US) - 5/26/2020 6:45:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/20/2020 9:09:24 AM
Results of GERAS-US Study Demonstrate Societal Cost Burden for Patients and Caregivers During Early Stages of Alzheimer's Dis... PR Newswire (US) - 5/19/2020 9:00:00 AM
Lilly Oncology Showcases Innovation in Cancer Research at ASCO 2020 PR Newswire (US) - 5/13/2020 5:00:00 PM
Mail-Order Drug Delivery Rises During Coronavirus Lockdowns Dow Jones News - 5/12/2020 7:29:00 AM
Drug Sales To Doctors Forced to Go Virtual -- WSJ Dow Jones News - 5/12/2020 3:02:00 AM
Drugmakers Overhaul the Sales Pitch Amid Coronavirus Lockdowns Dow Jones News - 5/11/2020 7:29:00 AM
Lilly Receives U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically for Patients with Advanced RE... PR Newswire (US) - 5/8/2020 8:22:00 PM
FDA Approves Eli Lilly Subsidiary's Retevmo to Treat Certain Cancer Patients Dow Jones News - 5/8/2020 6:28:00 PM
Eli Lilly Says Higher Trulicity Doses Reduced A1C, Weight in People with Type 2 Diabetes Dow Jones News - 5/8/2020 3:45:00 PM
Higher investigational doses of Trulicity® (dulaglutide) meaningfully reduced A1C and body weight in people with type 2 diab... PR Newswire (US) - 5/8/2020 2:20:00 PM
Tyvyt® (Sintilimab Injection) Combined with Gemzar® (Gemcitabine for Injection) and Platinum Chemotherapy Met the Predefine... PR Newswire (US) - 5/6/2020 7:30:00 PM
Lilly to Participate in UBS Virtual Global Healthcare Conference PR Newswire (US) - 5/5/2020 4:30:00 PM
Specialized Disclosure Report (sd) Edgar (US Regulatory) - 5/5/2020 1:59:51 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/5/2020 1:47:20 PM
ITMS Member Level  Thursday, 06/13/19 12:23:08 PM
Re: None
Post # of 102 
This Big Pharma Stock $LLY Is Dropping And Should Fall Further, Here's The Trade

Eli Lilly and Co (NYSE:LLY) is a leading pharmaceutical company that has been under pressure over the past couple of months. In fact, the stock topped on March 26, 2019 at $132.13 a share. Since that high pivot, the stock has declined by 14.0 percent and is currently trading at $112.84 a share. Traders and investors should note that LLY is now trading below its 50 and 200-day moving averages. This weak chart formation will usually signal further downside in the near term. The next key support level for LLY will be around the $105.00 area. This important level was defended in October and December 2018. Often, when a stock trades down to a major support area they will be defended again when initially retested.

Nick Santiago

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist